By ROC analysis, NKCC and dipeptidyl peptidase/CD26 were identified as potential biomarkers for CFS through their demonstrated accuracy in discriminating CFS patients from healthy controls. This evidence concerns the gene DPP4 and myalgic encephalomeyelitis/chronic fatigue syndrome.